Premium
Treatment of Helicobacter pylori infection 2016
Author(s) -
O'Connor Anthony,
Fischbach Wolfgang,
Gisbert Javier P.,
O'Morain Colm
Publication year - 2016
Publication title -
helicobacter
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.206
H-Index - 79
eISSN - 1523-5378
pISSN - 1083-4389
DOI - 10.1111/hel.12342
Subject(s) - helicobacter pylori , medicine , intensive care medicine , disease , peptic ulcer , cancer , antibiotic resistance , antibiotics , biology , microbiology and biotechnology
Many interesting articles have been published from different parts of the world over the last year assessing various issues around Helicobacter pylori eradication therapy. This article will address the published literature over the last year pertaining to the topic of treatment of H. pylori infection. The main themes that emerge are assessing the efficacy of standard triple therapy, as well as exploring new first‐line treatments, mainly optimized nonbismuth‐containing and bismuth‐containing quadruple therapies with some promising data also emerging on dual therapy. There was also considerable progress in investigating antibiotic resistance rates with much more data emerging from varied parts of the world compared to recent years. Advances in the use of adjunctive therapies, especially probiotic therapies have also been made. Undoubtedly, the eradication of H. pylori remains a worthwhile goal to alleviate the burden of diseases caused by the complications of this infection, including dyspepsia, peptic ulcer disease, and gastric cancer.